Answers are grounded in this paper and cite their sources.
Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy with high heterogeneity and poor outcomes. In this study, we searched for the new biomarker to promote the efficacy of diagnosis, therapy and prognosis of AML by transcriptome and clinical information from the Cancer Genome Atlas (TCGA) database, Gene Expression Omnibus (GEO) datasets, and Genotype-Tissue Expression (GTEx) projects. RFESD was found to be significantly downregulated in AML, and was confirmed as an independent prognostic factor by univariate Cox regression. A survival prediction nomogram was established with a C-index of 0.762, which indicated reliable prognostic prediction. Function pathway enrichment analysis of differentially expressed genes (DEGs) indicated immune response related pathways in low RFESD expression group. Through gene co-expression and protein‒protein interaction (PPI) network analysis, we identified KLF1 as the hub gene, which was linked to adverse clinical outcomes. Furthermore, we found that low expression of RFESD tended to be positively correlated with immune cells and immune check-points. Finally, drug sensitivity prediction indicated some inhibitors associated with cell-cycle and kinases. Accordingly, our research illustrated that the low expression level of RFESD predicts an adverse prognosis in AML patients.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: